TY - JOUR
T1 - Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program
T2 - harmonization priorities and strategies in a diverse international sample
AU - Allott, Kelly
AU - Yassin, Walid
AU - Alameda, Luis
AU - Billah, Tashrif
AU - Borders, Owen
AU - Buccilli, Kate
AU - Carrión, Ricardo E
AU - Castillo-Passi, Rolando I
AU - Cho, Kang Ik K
AU - Chin, Kota
AU - Coleman, Michael J
AU - Colton, Beau-Luke
AU - Corral, Sebastián
AU - Dwyer, Dominic
AU - Gundersen, Kristina Ballestad
AU - Gur, Ruben C
AU - Hoftman, Gil D
AU - Jacobs, Grace R
AU - Kelly, Sinead
AU - Lewandowski, Kathryn E
AU - Marcy, Patricia J
AU - Matneja, Priya
AU - McLaughlin, Danielle
AU - Nunez, Angela R
AU - Parsa, Setari
AU - Penzel, Nora
AU - Ray, Susan
AU - Reinen, Jenna M
AU - Ruparel, Kosha
AU - Sand, Michael S
AU - Santorelli, Gennarina
AU - Seitz-Holland, Johanna
AU - Spark, Jessica
AU - Tamayo, Zailyn
AU - Thompson, Andrew
AU - Tod, Sophie
AU - Wannan, Cassandra M J
AU - Wickham, Alana
AU - Wood, Stephen J
AU - Zoupou, Eirini
AU - Addington, Jean
AU - Anticevic, Alan
AU - Arango, Celso
AU - Breitborde, Nicholas J K
AU - Broome, Matthew R
AU - Cadenhead, Kristin S
AU - Calkins, Monica E
AU - Chen, Eric Yu Hai
AU - Choi, Jimmy
AU - Kahn, Rene S
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/3/24
Y1 - 2025/3/24
N2 - Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.
AB - Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.
U2 - 10.1038/s41537-025-00578-1
DO - 10.1038/s41537-025-00578-1
M3 - Article
C2 - 40128256
VL - 11
JO - Schizophrenia
JF - Schizophrenia
IS - 1
M1 - 49
ER -